Recombinant Full-length Human IgG1s Targeting Hormone-refractory Prostate Cancer

Overview

Journal J Mol Med (Berl)

Specialty General Medicine

Date 2007 Jun 8

PMID 17554518

Citations 21

Authors

Bin Liu

Fraser Conrad

Audrey Roth

Daryl C Drummond

Jeff P Simko

James D Marks

Affiliations

Soon will be listed here.

Abstract

We have used a naive human single-chain fragment variable (scFv) library as a source of random shape repertoire to directly probe the altered surface chemistry of tumor cells. We reported previously the identification of more than 90 internalizing phage monoclonal antibodies targeting prostate cancer cells, including those that are hormone refractory. In this report, we describe the conversion of a panel of those scFvs into full-length human immunoglobulins (IgGs) and show that tumor specificity is retained. We have further shown that antibodies isolated from a naive phage display library can nevertheless be of high affinity towards target tumor cells. In addition, full-length IgGs retain the functionality of parental scFvs including the ability to rapidly enter target cells through receptor-mediated endocytosis and thereby to mediate efficient and specific intracellular payload delivery to tumor cells. We have used recombinant IgGs to immunoprecipitate target antigens and analyzed their molecular composition by mass spectrometry. We have identified one target antigen as activated leukocyte cell adhesion molecule (ALCAM)/MEMD/CD166 and have further studied tissue specificity of this internalizing ALCAM epitope by immunohistochemistry. Our study shows that cell type-specific internalizing human antibody can be readily identified from a naive phage antibody display library, characterized with regards to sequence, affinity, tissue specificity, and antigen identity, and modified genetically and chemically to generate various forms of targeted therapeutics.

Citing Articles

Simultaneous Maturation of Single Chain Antibody Stability and Affinity by CHO Cell Display.

Luo R, Qu B, An L, Zhao Y, Cao Y, Ren P Bioengineering (Basel). 2022; 9(8).

PMID: 36004885 PMC: 9404881. DOI: 10.3390/bioengineering9080360.

Binding Characteristic of Various Antibody Formats Against Aflatoxins.

Rangnoi K, Ruker F, Wozniak-Knopp G, Cvak B, OKennedy R, Yamabhai M ACS Omega. 2021; 6(39):25258-25268.

PMID: 34632185 PMC: 8495687. DOI: 10.1021/acsomega.1c03044.

Endophilin-A3 and Galectin-8 control the clathrin-independent endocytosis of CD166.

Renard H, Tyckaert F, Lo Giudice C, Hirsch T, Valades-Cruz C, Lemaigre C Nat Commun. 2020; 11(1):1457.

PMID: 32193381 PMC: 7081352. DOI: 10.1038/s41467-020-15303-y.

Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.

Su Y, Liu Y, Behrens C, Bidlingmaier S, Lee N, Aggarwal R JCI Insight. 2018; 3(17).

PMID: 30185663 PMC: 6171802. DOI: 10.1172/jci.insight.121497.

Cell-type specific potent Wnt signaling blockade by bispecific antibody.

Lee N, Zhang Y, Su Y, Bidlingmaier S, Sherbenou D, Ha K Sci Rep. 2018; 8(1):766.

PMID: 29335534 PMC: 5768681. DOI: 10.1038/s41598-017-17539-z.

References

Simmons L, Reilly D, Klimowski L, Shantha Raju T, Meng G, Sims P . Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods. 2002; 263(1-2):133-47. DOI: 10.1016/s0022-1759(02)00036-4. View

Fair W, Israeli R, Heston W . Prostate-specific membrane antigen. Prostate. 1997; 32(2):140-8. DOI: 10.1002/(sici)1097-0045(19970701)32:2<140::aid-pros9>3.0.co;2-q. View

Chen L, Liebman M, Teodorescu-Frumosu S, Schnitzler A, Sharon J . Expression of a prototypic anti-colorectal cancer polyclonal antibody library in mammalian cells. Immunol Lett. 2003; 88(2):135-40. DOI: 10.1016/s0165-2478(03)00070-1. View

Horak E, Heitner T, Robinson M, Simmons H, Garrison J, Russeva M . Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. Cancer Biother Radiopharm. 2006; 20(6):603-13. DOI: 10.1089/cbr.2005.20.603. View

Carter P . Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2002; 1(2):118-29. DOI: 10.1038/35101072. View

BARTLETT G . Phosphorus assay in column chromatography. J Biol Chem. 1959; 234(3):466-8. View

Reiter R, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E . Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A. 1998; 95(4):1735-40. PMC: 19171. DOI: 10.1073/pnas.95.4.1735. View

Thompson J, Vaughan T, Williams A, Wilton J, Johnson K, Bacon L . A fully human antibody neutralising biologically active human TGFbeta2 for use in therapy. J Immunol Methods. 1999; 227(1-2):17-29. DOI: 10.1016/s0022-1759(99)00060-5. View

Saffran D, Raitano A, Hubert R, Witte O, Reiter R, Jakobovits A . Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A. 2001; 98(5):2658-63. PMC: 30194. DOI: 10.1073/pnas.051624698. View

10.

Miescher S, De Jesus M, Moudry R, Fisch I, Vogel M, Kobr M . CHO expression of a novel human recombinant IgG1 anti-RhD antibody isolated by phage display. Br J Haematol. 2000; 111(1):157-66. DOI: 10.1046/j.1365-2141.2000.02322.x. View

11.

Poul M, Becerril B, Nielsen U, Morisson P, Marks J . Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol. 2000; 301(5):1149-61. DOI: 10.1006/jmbi.2000.4026. View

12.

Nowakowski A, Wang C, Powers D, Amersdorfer P, Smith T, Montgomery V . Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A. 2002; 99(17):11346-50. PMC: 123259. DOI: 10.1073/pnas.172229899. View

13.

Liu G, Dou S, He J, Vanderheyden J, Rusckowski M, Hnatowich D . Preparation and properties of 99mTc(CO)3+-labeled N,N-bis(2-pyridylmethyl)-4-aminobutyric acid. Bioconjug Chem. 2004; 15(6):1441-6. PMC: 1584306. DOI: 10.1021/bc049866a. View

14.

Drummond D, Meyer O, Hong K, Kirpotin D, Papahadjopoulos D . Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999; 51(4):691-743. View

15.

Degen W, van Kempen L, Gijzen E, van Groningen J, van Kooyk Y, Bloemers H . MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol. 1998; 152(3):805-13. PMC: 1858405. View

16.

Huls G, Heijnen I, Cuomo M, Koningsberger J, Wiegman L, Boel E . A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat Biotechnol. 1999; 17(3):276-81. DOI: 10.1038/7023. View

17.

Nielsen U, Kirpotin D, Pickering E, Hong K, Park J, Shalaby M . Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta. 2002; 1591(1-3):109-118. DOI: 10.1016/s0167-4889(02)00256-2. View

18.

Spiridon C, Guinn S, Vitetta E . A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies. Clin Cancer Res. 2004; 10(10):3542-51. DOI: 10.1158/1078-0432.CCR-03-0549. View

19.

Bradbury A . Evolution of the display technologies. Trends Biotechnol. 2000; 18(5):183-4. DOI: 10.1016/s0167-7799(99)01408-0. View

20.

Piazza T, Cha E, Bongarzone I, Canevari S, Bolognesi A, Polito L . Internalization and recycling of ALCAM/CD166 detected by a fully human single-chain recombinant antibody. J Cell Sci. 2005; 118(Pt 7):1515-25. DOI: 10.1242/jcs.02280. View